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Respiratory decline is integral to disease
progression in Huntington’s disease
To the Editor:
Huntington’s disease is an autosomal inherited monogenetic condition in which the mutation is an
expansion of the cytosine-adenine-guanine (CAG) repeat sequence at the N-terminal end of the huntingtin
gene [1]. More than 40 repeats are associated with neuronal dysfunction and death, predominantly within
the striatum resulting in a triad of movement, behaviour and cognitive impairment; other symptoms include
weight loss, sleep disturbance and respiratory dysfunction, which may or may not be of primary neurological
origin [1–3]. Death occurs 15–30 years after onset of symptoms [1], usually due to pneumonia [4], yet it is
not known whether respiratory dysfunction is a feature of late stage disease or whether it appears earlier
in the disease evolution. Previous research suggests that dysregulation within the respiratory centre results in
irregular breathing patterns [5, 6]; decreased respiratory muscle strength and lung volumes have also been
identified [7] which, alongside swallow dysfunction [4], could precipitate respiratory failure. Huntington’s
disease is a complex long-term condition and contributing factors such as swallow dysfunction, posture,
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physical inactivity and reduced exercise capacity have not yet been investigated in relation to respiratory
function. We conducted a cross-sectional study aiming to characterise respiratory function across all stages
of disease and explore primary and secondary contributors to respiratory decline. Given one previous report
of respiratory weakness in Huntington’s disease, we performed a follow-on study to assess the feasibility of
home-based inspiratory muscle training in Huntington’s disease.
67 participants testing positive for the Huntington’s disease gene were recruited to the cross-sectional
study from the South Wales Huntington’s disease clinic (Cardiff, UK) between July 2009 and December
2012. Inclusion criteria were: CAG repeat ⩾40; aged ⩾18 years; able to understand instructions in English;
and maintenance of a stable medical regime for 4 weeks prior to the study. Healthy controls (n=39;
matched for age, sex, smoking pack-years and fat-free mass) were recruited from relatives, carers and
members of Cardiff University. Informed consent was obtained under the Research Ethics Committee for
Wales (08/MRE09/65).
Huntington’s disease-positive participants were categorised as pre-manifest or manifest based on the presence
of motor abnormalities representing an unequivocal diagnosis of Huntington’s disease; disease severity was
categorised by the Unified Huntington’s Disease Rating Scale (total functional capacity scale ranging 0–13) [8].
Outcome measures were: forced vital capacity; forced expiratory volume in 1 s (FEV1)/peak expiratory flow
rate (PEFR) ratio; peak cough flow (PCF); maximal inspiratory pressure (MIP); sniff nasal inspiratory pressure
(SNIP), maximal expiratory pressure; swallow capacity measured as mL·s-1 during timed swallow of 150 mL of
water [9]; metabolic equivalents via the international physical activity questionnaire (short form) [10]; 6-min
walk distance (20-m circuit); and thoracic posture via bespoke digital analysis [11].
Statistically significant differences were found for all respiratory function variables across healthy,
pre-manifest and manifest participants (table 1). Post hoc analyses identified decreased respiratory function
in the manifest group compared to healthy controls and pre-manifest groups, with no differences between
healthy controls and pre-manifest. Analysis of FEV1/PEFR showed that eight (40%) pre-manifest and
26 (55.3%) manifest participants had a ratio of >8, indicative of central or upper airway obstruction [12]. In
manifest participants with Huntington’s disease, all measures of respiratory function significantly correlated
with disease progression (Spearman’s r=0.716–0.863, p<0.001) (figure 1). Regression analysis indicated PCF
<270 L·min−1 [13] when total functional capacity was 5, i.e. middle stage of the disease, suggesting that
respiratory intervention may be warranted earlier in the disease process than typically considered.
Percentage predicted swallow capacity, thoracic angle, physical activity and exercise capacity significantly
correlated with respiratory function in manifest participants (Spearman’s r=0.465–0.790, p<0.001). Swallow
capacity was normal in all pre-manifest participants and abnormal in 39 (84.8%) manifest participants with
Huntington’s disease. Physical activity scores were categorised as moderate (median=1502.50 metabolic
equivalent minutes·week-1; interquartile range (IQR) 2418.4) for people with pre-manifest Huntington’s
disease and low (82.50 metabolic equivalent minutes·week-1; IQR 618.80) for people with manifest disease.
6-min walk distance was 78.63% predicted and 27.73% predicted for pre-manifest and manifest participants
with Huntington’s disease, respectively.
TABLE 1 Comparison of healthy controls, pre-manifest and manifest participants
Healthy controls Pre-manifest Manifest
Subjects 39 20 47
FVC L 3.59±0.92 (3.29–3.88) 3.93±0.97 (3.48–4.38) 2.14±1.39#,¶ (1.74–2.55)
FVC % pred 94.00±15.89 101.15±13.84 56.70±31.69#,¶
FEV1 L 3.02±0.83 (2.75–3.29) 3.31±0.79 (2.94–3.68) 1.88±1.20#,¶ (1.53–2.23)
FEV1 % pred 95.26±14.88 101.35±15.19 60.51±33.94#,¶
PEFR L·min-1 457.41±113.22 (420.71–494.11) 435.05±139.73 (369.66–500.44) 221.49±141.61#,¶ (179.91–263.07)
PEFR % pred 100.13±18.71 92.60±24.63 49.49±29.53#,¶
PCF L·min-1 433.95±102.48 (400.73–467.17) 504.55±124.12 (446.46–562.64) 269.46±154.5#,¶ (220.67–318.25)
MIP cmH2O 83.00±31.43 (72.67–93.33) 87.00±30.33 (72.38–101.62) 25.60±21.41
#,¶ (19.31–31.88)
MIP % pred 95.29±32.27 97.68±29.45 29.31±24.25#,¶
SNIP cmH2O 74.13±31.68 (63.72–84.54) 81.32±33.22 (65.31–97.33) 34.42 ± 23.63
#,¶ (27.15–41.69)
SNIP % pred 77.97±32.84 85.29±32.69 36.65±26.62#,¶
Data are presented as mean±SD with 95% confidence intervals. FVC: forced vital capacity; FEV1: forced expiratory volume in 1 s; PEFR: peak
expiratory flow rate; PCF: peak cough flow; MIP: maximal inspiratory pressure; SNIP: sniff nasal inspiratory pressure. #: difference between
healthy control and manifest p<0.001; ¶: difference between pre-manifest and manifest p<0.001.
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Participants for the follow-on training pilot were selected from the cross-sectional cohort (Ethics: 11/WA/
0183; and ISCRTN90741776). Inclusion and exclusion criteria were as for the cross-sectional study,
additionally participants were excluded if they were pre-symptomatic and had an MIP >80% pred. 20
participants were randomly allocated to intervention or placebo using a minimisation method [14] to match
for age, sex and smoking habit and were blinded to group allocation. The intervention group (n=10) used the
POWERbreathe®K3 device (POWERbreathe International Ltd, Southam, UK) for 30 breaths, twice a day at a
resistance of 50% of MIP for 6 weeks; resistance was set at 10 cmH2O for the placebo group. The
POWERbreathe®K3 device automatically sets resistance based on MIP pressures generated in the first two
inspirations. Although resistance based on SNIP would have been more appropriate for the sample, this
device provided resistance throughout the range of movement of the inspiratory muscles. A habituation
period of 1 week preceded the study. Participants were instructed by the researcher who provided support
through alternate weekly phone calls and home visits. The primary outcome measure was SNIP and the
secondary outcome was cough efficacy as measured by PCF, the measurement was not blinded. Adherence
was measured as number of training sessions as recorded by the POWERbreathe®K3 device.
All participants had MIP and SNIP <80% pred. Adherence to inspiratory muscle training was similar for
both intervention and placebo groups: 70.67±26.35% and 74.53±21.03%, respectively. For those that
completed the study, SNIP increased from 47.60±33.96 cmH2O to 53.60±28.31 cmH2O (intervention: n=5)
and from 46.00±20.06 cmH2O to 53.00±18.17 cmH2O (placebo: n=7) and PCF increased from
415.80±153.57 L·min−1 to 448±144.97 L·min−1 (intervention) and from 334.00±101.64 L·min−1 to
370.71±89.00 L·min−1 (placebo). With nonsignificant increases in SNIP and PCF within both groups,
further analyses were conducted pooling the groups to explore whether participating in the programme,
irrespective of resistance, changed respiratory function. Post-intervention mean difference for SNIP was
8.07 cmH2O (effect size 0.36) and PCF 49.39 L·min
−1 (effect size 0.37). The small effect sizes suggest that
regular breathing exercises, irrespective of added resistance, could improve cough efficacy and respiratory
muscle strength.
We present data that gives a clear indication that respiratory failure in Huntington’s disease is not simply a
consequence of a neurodegenerative condition. The decline in respiratory function is integral to the disease
process and we suggest that regular breathing exercises may increase the capacity of the respiratory
muscles and improve cough effectiveness. This study expands on previous research findings of reduced
lung volume and respiratory muscle strength in Huntington’s disease [7] by identifying that: upper airway
changes occur in pre-manifest Huntington’s disease; cough effectiveness is reduced in the mid stage of the
disease; and posture, physical activity and exercise capacity influence respiratory function in Huntington’s
disease. Our data provides a holistic representation of respiratory function in Huntington’s disease across
the disease life cycle. We present comprehensive data of physiological variables of decreased lung volume
and respiratory muscle strength and upper airway obstruction that are responsible for respiratory failure in
people with Huntington’s disease and suggest that clinicians monitor respiratory function from at least the
middle stage of the disease. Further research is needed to identify the appropriate interventional strategies
based on confirmation of feasibility and effectiveness of regular breathing exercises in this study.
@ERSpublications
Respiratory function in Huntington’s disease should be monitored from middle stage to preclude
respiratory failure http://ow.ly/YXTt300mIQw
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FIGURE 1 Respiratory function and disease progression in people with manifest Huntington’s disease.
a) Respiratory muscle strength and total functional capacity (TFC). b) Lung volume and TFC. MIP: maximal
inspiratory pressure; FVC: forced vital capacity.
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